Talazoparib Reduces Progression of BRCA1/2 Positive Breast Cancer

The agent Talazoparib reduces progression of cancer among women with advanced BRCA1 or BRCA2 positive breast cancers when compared to standard chemotherapy.
Read the article from the New England Journal of Medicine here:

Leave a Reply

Your email address will not be published. Required fields are marked *